Leadership Overview
Ipsen has 5 executives leading key functions including finance, marketing, quality, and opinion leadership.
Driven by innovation, Ipsen is dedicated to developing and commercializing specialty medicines in oncology, neuroscience, and rare diseases, impacting global health outcomes.
Driven by innovation, Ipsen is dedicated to developing and commercializing specialty medicines in oncology, neuroscience, and rare diseases, impacting global health outcomes.
Leadership Roles at Ipsen
Gonzalo Colimodio - Chief Financial Officer
Gonzalo Colimodio, the Chief Financial Officer at Ipsen, directs the company's financial strategy and operations. Colimodio oversees all fiscal activities, including financial planning, budgeting, and reporting, ensuring robust financial health and compliance across global markets. This leadership role involves managing capital allocation and driving initiatives that support sustainable growth and profitability. By optimizing financial structures, Gonzalo Colimodio directly contributes to Ipsen's ability to fund research and development for its specialty care medicines in oncology, neuroscience, and rare diseases. The Chief Financial Officer's oversight extends to investor relations and maintaining strong relationships with financial institutions, crucial for securing resources to advance the company's therapeutic pipeline and market expansion efforts.
Andrew Singer - Executive Vice President & Chief Financial Officer
Andrew Singer, the Executive Vice President & Chief Financial Officer at Ipsen, provides critical financial leadership and strategic oversight for the biopharmaceutical group. Singer directs the financial planning, analysis, and reporting functions, ensuring fiscal discipline and resource optimization to support Ipsen's growth objectives in oncology, neuroscience, and rare diseases. This executive role involves managing corporate finance, treasury operations, and capital markets activities, crucial for funding research, development, and global commercialization efforts. By guiding financial strategy, Andrew Singer ensures Ipsen maintains a strong financial position to pursue strategic acquisitions and partnerships that enhance its therapeutic pipeline. The Executive Vice President & Chief Financial Officer's expertise is fundamental to driving shareholder value and sustaining the company's commitment to specialty care innovation.
Koceir Hichem - Chief Marketing Officer, Quality
Koceir Hichem, the Chief Marketing Officer, Quality at Ipsen, spearheads the strategic direction for marketing initiatives while ensuring the highest standards of quality across all product lines. Hichem directs the development and execution of comprehensive marketing plans designed to enhance brand visibility and market penetration for Ipsen's specialty care portfolio, particularly in oncology and neuroscience. This dual focus ensures that marketing efforts are intrinsically linked to product integrity and patient safety. Overseeing quality assurance processes, Koceir Hichem guarantees that all commercial activities align with stringent regulatory requirements and company standards. The Chief Marketing Officer, Quality's leadership is vital for communicating the value of Ipsen's innovative treatments to healthcare professionals and patients globally, fostering trust and driving adoption.
Farida Bouziane - Chief Marketing Officer & Manager, Quality Snior & , Africa (North)
Farida Bouziane, the Chief Marketing Officer & Manager, Quality Snior & , Africa (North) at Ipsen, drives marketing strategies and quality management for the North African region. Bouziane develops and implements targeted marketing campaigns to promote Ipsen's specialty medicines, focusing on therapeutic areas such as oncology and neuroscience within the specified geographic market. This leadership role ensures that marketing efforts are aligned with regional healthcare needs and regulatory landscapes. Simultaneously, Farida Bouziane oversees quality assurance protocols, guaranteeing adherence to high standards in product distribution and commercial practices across North Africa. The Chief Marketing Officer & Manager, Quality Snior & , Africa (North)'s integrated approach strengthens Ipsen's presence and commitment to patient access in this key market.
Riekie Smit - Trainer & Key Opinion Leader
Riekie Smit, the Trainer & Key Opinion Leader at Ipsen, plays a pivotal role in disseminating specialized knowledge and fostering best practices within the biopharmaceutical community. Smit focuses on educating healthcare professionals and internal teams on the clinical applications and therapeutic benefits of Ipsen's innovative medicines, particularly in oncology and rare diseases. This involves developing and delivering comprehensive training programs that enhance understanding and utilization of specialty care treatments. As a Key Opinion Leader, Riekie Smit contributes valuable insights and expertise, influencing scientific discourse and promoting the adoption of advanced therapeutic approaches. The Trainer & Key Opinion Leader's engagement is critical for advancing medical education and ensuring optimal patient outcomes through informed clinical practice.
Explore Leadership Teams in Manufacturing
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership HH
JK
MC
MB
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
AC
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Galderma is a global dermatology company focused exclusively on skin health, combining scientific innovation with consumer‑ and patient‑driven solutions. It develops and markets a comprehensive range of products and treatments across three main business areas injectable aesthetics, dermatological skincare, and therapeutic dermatology to address both cosmetic and medical skin conditions. Galderma partners closely with healthcare professionals worldwide to deliver science‑based care tailored to individual skin needs, from daily skincare and aesthetic treatments to prescription therapies. With a broad international presence and a heritage rooted in dermatological research, the company aims to advance skin health for people across different stages of life.
Company Leadership CK
BF
Frequently Asked Questions Regarding Ipsen Top Executives and Leadership Team
